OP3-10 IMPACT OF BLEOMYCIN ON RETROPERITONEAL HISTOLOGY AT POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PC-RPLND) IN GOOD RISK GERM CELL TUMORS

Abstract

You have accessJournal of UrologyOutstanding Posters: Oncology1 Apr 2014OP3-10 IMPACT OF BLEOMYCIN ON RETROPERITONEAL HISTOLOGY AT POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PC-RPLND) IN GOOD RISK GERM CELL TUMORS K. Clint Cary, Jose Pedrosa, Hristos Kaimakliotis, TImothy Masterson, Lawrence Einhorn, and Richard Foster K. Clint CaryK. Clint Cary More articles by this author , Jose PedrosaJose Pedrosa More articles by this author , Hristos KaimakliotisHristos Kaimakliotis More articles by this author , TImothy MastersonTImothy Masterson More articles by this author , Lawrence EinhornLawrence Einhorn More articles by this author , and Richard FosterRichard Foster More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.2331AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Induction chemotherapy for International Germ Cell Cancer Collaborative Group (IGCCCG) good risk metastatic testicular cancer includes either 3 cycles of bleomycin, etoposide, and cisplatin (BEP) or 4 cycles of etoposide and cisplatin (EP). We sought to examine the differences in active cancer in the retroperitoneum (RP) between patients receiving BEPx3 compared to EPx4. METHODS The Indiana University Testis Cancer database was queried to identify IGCCCG good risk patients who received either BEPx3 or EPx4 induction chemotherapy prior to PC-RPLND. The primary outcome of RP histology was categorized as active cancer (yes/no). The association between use of bleomycin in the induction regimen with active cancer in the RP was tested with logistic regression. A propensity score-adjusted analysis was undertaken to adjust for potential imbalances among men receiving BEP or EP. RESULTS A total of 226 patients met inclusion criteria, some of which were treated at outside institutions. One hundred seventy-nine men (79%) received BEPx3 while 47 (21%) received EPx4. The median age of the BEP group was 27 years (range: 15-50) compared to 30 years (range: 18-71) in the EP group. The BEP group had surgery in earlier years, more often had a right sided primary tumor, and a component of embryonal cell carcinoma in the primary tumor (all p<0.05). The incidence of active cancer in the RP specimen at PC-RPLND was significantly higher in the EPx4 group compared to the BEPx3 group (31.9% vs. 7.8%, p<0.01). This significant difference between the BEP and EP groups remained in the propensity-adjusted analysis (25.5% vs. 8.4%, p=0.01). CONCLUSIONS There was a higher incidence of active cancer in the RP specimen in good risk patients who receive 4 cycles of induction EP chemotherapy compared to men receiving 3 cycles of BEP in this retrospective analysis. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e855 Advertisement Copyright & Permissions© 2014MetricsAuthor Information K. Clint Cary More articles by this author Jose Pedrosa More articles by this author Hristos Kaimakliotis More articles by this author TImothy Masterson More articles by this author Lawrence Einhorn More articles by this author Richard Foster More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...